ViroCell Biologics
PrivateLast Round
Convertible Debt
Aug 14, 2024
Company Overview
ViroCell Biologics operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Convertible Debt round in August 2024.
ViroCell Biologics is a biotechnology company that operates as a contract development and manufacturing organization (CDMO) focused on the design, optimization, and GMP manufacturing of lentiviral and retroviral vectors for cell and gene therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ViroCell Biologics Comparables
Compare ViroCell Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vector BioMed, Inc. | 93% | |
| Genezen | 89% | |
| VIVEbiotech | 89% |
For institutional investors. Book with your work email.
ViroCell Biologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Aug 14, 2024 | ||||
| Seed | Apr 28, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ViroCell Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Disruptive Capital | Seed |
| Truell Conservation Foundation | Seed |
| First Light Asset Management | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 2, 2025
Monthly visitors increased 536% MoM, reaching 8.9K.
- Mar 24, 2025
Monthly visitors increased 42% MoM.
For institutional investors. Book with your work email.
ViroCell Biologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ViroCell Biologics's valuation, stock price, and market status.
Is ViroCell Biologics a public or private company?
ViroCell Biologics is a private company.
What is the current stock price of ViroCell Biologics?
ViroCell Biologics is a private company, so its shares have no public market price. Caplight tracks ViroCell Biologics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ViroCell Biologics worth (valuation)?
Valuation information for ViroCell Biologics is not publicly available.
Can I buy ViroCell Biologics stock?
ViroCell Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ViroCell Biologics's last funding round?
ViroCell Biologics's most recent funding round was Convertible Debt on August 14, 2024.
Who are the main investors in ViroCell Biologics?
Key investors in ViroCell Biologics include First Light Asset Management.
Will ViroCell Biologics IPO soon?
No public IPO plans have been announced for ViroCell Biologics.
How can I track ViroCell Biologics secondary market activity?
Caplight tracks bids, offers, and trades in ViroCell Biologics's shares on secondary markets.